Abstract
Parkinson’s disease (PD) is increasingly linked to gut dysbiosis, proinflammatory microbiome profiles, and intestinal barrier dysfunction. While microbiota-produced short-chain fatty acids (SCFAs) are known to promote immune regulation and gut health, their therapeutic potential in PD has remained largely unexplored. This randomized, double-blind prospective study evaluated the effects of supplementing 72 PD patients with SCFAs and/or the prebiotic fiber 2′-fucosyllactose (2FL) over six months. The intervention led to significant improvements in both motor and non-motor symptoms, alongside enhanced mitochondrial respiration in immune cells and systemic immunomodulation. Notably, these benefits occurred without a wholesale restructuring of the gut microbiome, suggesting direct metabolic and signaling roles for SCFAs. These findings highlight SCFA supplementation as a promising, well-tolerated add-on therapy for PD.
Introduction
Parkinson’s Disease is no longer viewed solely as a neurological disorder but as a systemic condition involving the "gut-brain axis." PD patients frequently exhibit a reduction in bacteria that produce short-chain fatty acids (SCFAs), such as butyrate and propionate. These metabolites are critical for maintaining the intestinal barrier and regulating systemic inflammation. This study aimed to determine if direct supplementation with these missing metabolites or their prebiotic precursors could move the needle on clinical markers like motor function, medication requirements, and cognitive health.
Methods
The researchers conducted a six-month randomized, double-blind study involving 72 PD patients divided into three arms: prebiotic fiber (2FL) alone, direct SCFA supplementation (Propionic and Butyric Acid), or a combination of both.
To analyze the results, the team employed several advanced techniques:
- Multiobjective Analysis (MOA): Using Pareto fronts to identify "responders" who improved across multiple, sometimes conflicting, clinical metrics (e.g., motor scores vs. olfaction).
- Machine Learning: An XGBoost classifier was used to predict treatment response based on baseline microbiome composition.
- Deep Phenotyping: The study combined metagenomic sequencing with high-dimensional immunophenotyping and Seahorse assays to measure mitochondrial respiration in peripheral blood mononuclear cells (PBMCs).
Results
Clinical Gains and Medication Reduction
All intervention groups showed a significant improvement in motor function, evidenced by a decrease in MDS-UPDRS III scores. Furthermore, there was a significant reduction in the Levodopa Equivalent Daily Dose (LEDD) required by patients, suggesting the supplements acted as an effective "add-on" therapy that could potentially lower the burden of standard medications.
Non-Motor Improvements
Cognitive function (measured by PANDA scores) improved across all groups. Interestingly, olfaction—a common non-motor symptom in PD—showed specific improvement in the 2FL and combination therapy groups.
Mechanisms: Mitochondrial Rescue and Immune Shifts
Crucially, the clinical improvements occurred without significant changes to the overall microbiome diversity. Instead, the benefits appeared to be driven by direct systemic effects. SCFA supplementation improved mitochondrial respiration in immune cells, addressing a core hallmark of PD pathology. Immunophenotyping revealed that "responders" exhibited an increase in Mucosal-Associated Invariant T (MAIT) cells and a decrease in intermediate monocytes, signaling a shift toward a less inflammatory environment.
Predicting Success
The XGBoost model achieved an AUC of 0.83 in predicting responders for the combination therapy. The model revealed a "deficit hypothesis": patients with the lowest baseline levels of SCFA-producing bacteria stood to gain the most from the intervention, suggesting that stool samples could eventually serve as a screening tool for this treatment.
Discussion and Limitations
This exploratory study demonstrates that SCFA and prebiotic supplementation is a promising disease-modifying strategy for PD. While the study did not find elevated SCFA levels in serum or feces at the six-month mark—likely due to rapid host metabolism—the systemic impact on immunity and cellular energy was clear.
Limitations include the exploratory nature of the statistical analysis and the small size of the validation cohort for cellular assays. Future Phase III clinical trials are necessary to confirm these findings and explore the direct impact of these metabolites on the central nervous system via cerebrospinal fluid analysis.
Summary updated